Development
Acrivon Therapeutics, Inc.
ACRV
$1.35
$0.108.00%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.59M | 15.35M | 12.20M | 8.71M | 5.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.00M | 49.43M | 39.84M | 32.66M | 26.98M |
| Operating Income | -56.00M | -49.43M | -39.84M | -32.66M | -26.98M |
| Income Before Tax | -50.07M | -44.80M | -36.70M | -31.17M | -26.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.07 | -44.80 | -36.70 | -31.17 | -26.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.07M | -44.80M | -36.70M | -31.17M | -26.58M |
| EBIT | -56.00M | -49.43M | -39.84M | -32.66M | -26.98M |
| EBITDA | -55.48M | -48.94M | -39.39M | -32.29M | -26.73M |
| EPS Basic | -2.68 | -7.19 | -9.85 | -13.35 | -15.00 |
| Normalized Basic EPS | -1.74 | -4.57 | -6.23 | -8.38 | -9.37 |
| EPS Diluted | -2.68 | -7.19 | -9.85 | -13.35 | -15.00 |
| Normalized Diluted EPS | -1.74 | -4.57 | -6.23 | -8.38 | -9.37 |
| Average Basic Shares Outstanding | 77.07M | 56.76M | 36.56M | 16.41M | 7.09M |
| Average Diluted Shares Outstanding | 77.07M | 56.76M | 36.56M | 16.41M | 7.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |